Berlex Betaseron loses 20% of MS patients to Biogen Avonex -- Schering AG's Vita.
Executive Summary
BERLEX BETASERON LOSES 20% OF PATIENTS TO BIOGEN AVONEX since the introduction of the second interferon beta product in May 1996, Schering AG Chairman Giuseppe Vita said at a press conference in Berlin March 19. He said that as a result of the Avonex launch, "we recorded a decline of 6,000 patients." This "did not surprise us," Vita continued. "A loss of 20% during the transition from a situation as a sole supplier to a competition situation is nearer the lower limit of other experiences."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth